```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates the role of PARK2, an E3 ubiquitin ligase, as a tumor suppressor, contrasting its known role in Parkinson's disease where mutations lead to neuronal dysfunction. The disease mechanism in cancer involves the loss of PARK2's ubiquitin ligase activity, leading to dysregulation of cyclin E and promoting tumor cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism in cancer as the loss of PARK2's tumor suppressor function due to impaired ubiquitination activity, leading to increased cell growth and mitotic instability. This contrasts with the neuronal dysfunction seen in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses colony-forming assays, cell growth assays, xenograft studies, and ubiquitination assays to assess the impact of PARK2 mutations on tumor cell growth and cyclin E regulation.",
          "judgment": "Yes",
          "reasoning": "The assays used (colony-forming, cell growth, xenograft, and ubiquitination assays) are relevant to assessing the role of PARK2 as a tumor suppressor and its impact on cell proliferation and ubiquitination activity. These assays directly model the proposed disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type PARK2 as a normal/negative control and vector-only control. The paper explicitly states that multiple replicates were used for experiments.",
          "judgment": "Yes",
          "reasoning": "The study used a wild-type PARK2 control and a vector-only control. The assays were performed in triplicate, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study also included cancer-specific variants as controls. The study tests PARK2 with tumor-derived mutations resulted in substantially decreased colony-forming activity as compared to WT PARK2",
          "judgment": "No",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic variants independently of this study. Hence, we cannot proceed further with the PS3 evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using Student's t-test and ANOVA.",
          "judgment": "No",
          "reasoning": "The statistical analyses are insufficient to calculate OddsPath for the functional data for this variant. There is no OddsPath or similar measure calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests cancer associated variants for their colony forming ability, E3 ligase function and impact on ubiquitination of cyclin E.",
          "judgment": "Less than 10 pathogenic or benign controls.",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic or Benign/Likely Benign variants independently of this study. Since we don't have more than 10 known variants, the evidence is maxed at supporting.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R42C mutation compromises PARK2's ability to suppress tumor cell growth and impairs its E3 ligase function and this is PS3 supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "N",
          "alt": "S",
          "position": "254"
        },
        "variant_string_id": "PARK2 N254S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates the role of PARK2, an E3 ubiquitin ligase, as a tumor suppressor, contrasting its known role in Parkinson's disease where mutations lead to neuronal dysfunction. The disease mechanism in cancer involves the loss of PARK2's ubiquitin ligase activity, leading to dysregulation of cyclin E and promoting tumor cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism in cancer as the loss of PARK2's tumor suppressor function due to impaired ubiquitination activity, leading to increased cell growth and mitotic instability. This contrasts with the neuronal dysfunction seen in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses colony-forming assays, cell growth assays, xenograft studies, and ubiquitination assays to assess the impact of PARK2 mutations on tumor cell growth and cyclin E regulation.",
          "judgment": "Yes",
          "reasoning": "The assays used (colony-forming, cell growth, xenograft, and ubiquitination assays) are relevant to assessing the role of PARK2 as a tumor suppressor and its impact on cell proliferation and ubiquitination activity. These assays directly model the proposed disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type PARK2 as a normal/negative control and vector-only control. The paper explicitly states that multiple replicates were used for experiments.",
          "judgment": "Yes",
          "reasoning": "The study used a wild-type PARK2 control and a vector-only control. The assays were performed in triplicate, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study also included cancer-specific variants as controls. The study tests PARK2 with tumor-derived mutations resulted in substantially decreased colony-forming activity as compared to WT PARK2",
          "judgment": "No",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic variants independently of this study. Hence, we cannot proceed further with the PS3 evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using Student's t-test and ANOVA.",
          "judgment": "No",
          "reasoning": "The statistical analyses are insufficient to calculate OddsPath for the functional data for this variant. There is no OddsPath or similar measure calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests cancer associated variants for their colony forming ability, E3 ligase function and impact on ubiquitination of cyclin E.",
          "judgment": "Less than 10 pathogenic or benign controls.",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic or Benign/Likely Benign variants independently of this study. Since we don't have more than 10 known variants, the evidence is maxed at supporting.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The N254S mutation compromises PARK2's ability to suppress tumor cell growth and impairs its E3 ligase function and this is PS3 supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "Q",
          "position": "275"
        },
        "variant_string_id": "PARK2 R275Q"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates the role of PARK2, an E3 ubiquitin ligase, as a tumor suppressor, contrasting its known role in Parkinson's disease where mutations lead to neuronal dysfunction. The disease mechanism in cancer involves the loss of PARK2's ubiquitin ligase activity, leading to dysregulation of cyclin E and promoting tumor cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism in cancer as the loss of PARK2's tumor suppressor function due to impaired ubiquitination activity, leading to increased cell growth and mitotic instability. This contrasts with the neuronal dysfunction seen in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses colony-forming assays, cell growth assays, xenograft studies, and ubiquitination assays to assess the impact of PARK2 mutations on tumor cell growth and cyclin E regulation.",
          "judgment": "Yes",
          "reasoning": "The assays used (colony-forming, cell growth, xenograft, and ubiquitination assays) are relevant to assessing the role of PARK2 as a tumor suppressor and its impact on cell proliferation and ubiquitination activity. These assays directly model the proposed disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type PARK2 as a normal/negative control and vector-only control. The paper explicitly states that multiple replicates were used for experiments.",
          "judgment": "Yes",
          "reasoning": "The study used a wild-type PARK2 control and a vector-only control. The assays were performed in triplicate, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study also included cancer-specific variants as controls. The study tests PARK2 with tumor-derived mutations resulted in substantially decreased colony-forming activity as compared to WT PARK2",
          "judgment": "No",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic variants independently of this study. Hence, we cannot proceed further with the PS3 evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using Student's t-test and ANOVA.",
          "judgment": "No",
          "reasoning": "The statistical analyses are insufficient to calculate OddsPath for the functional data for this variant. There is no OddsPath or similar measure calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests cancer associated variants for their colony forming ability, E3 ligase function and impact on ubiquitination of cyclin E.",
          "judgment": "Less than 10 pathogenic or benign controls.",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic or Benign/Likely Benign variants independently of this study. Since we don't have more than 10 known variants, the evidence is maxed at supporting.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R275Q mutation compromises PARK2's ability to suppress tumor cell growth and impairs its E3 ligase function and this is PS3 supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "E",
          "alt": "G",
          "position": "344"
        },
        "variant_string_id": "PARK2 E344G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates the role of PARK2, an E3 ubiquitin ligase, as a tumor suppressor, contrasting its known role in Parkinson's disease where mutations lead to neuronal dysfunction. The disease mechanism in cancer involves the loss of PARK2's ubiquitin ligase activity, leading to dysregulation of cyclin E and promoting tumor cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism in cancer as the loss of PARK2's tumor suppressor function due to impaired ubiquitination activity, leading to increased cell growth and mitotic instability. This contrasts with the neuronal dysfunction seen in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses colony-forming assays, cell growth assays, xenograft studies, and ubiquitination assays to assess the impact of PARK2 mutations on tumor cell growth and cyclin E regulation.",
          "judgment": "Yes",
          "reasoning": "The assays used (colony-forming, cell growth, xenograft, and ubiquitination assays) are relevant to assessing the role of PARK2 as a tumor suppressor and its impact on cell proliferation and ubiquitination activity. These assays directly model the proposed disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type PARK2 as a normal/negative control and vector-only control. The paper explicitly states that multiple replicates were used for experiments.",
          "judgment": "Yes",
          "reasoning": "The study used a wild-type PARK2 control and a vector-only control. The assays were performed in triplicate, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study also included cancer-specific variants as controls. The study tests PARK2 with tumor-derived mutations resulted in substantially decreased colony-forming activity as compared to WT PARK2",
          "judgment": "No",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic variants independently of this study. Hence, we cannot proceed further with the PS3 evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using Student's t-test and ANOVA.",
          "judgment": "No",
          "reasoning": "The statistical analyses are insufficient to calculate OddsPath for the functional data for this variant. There is no OddsPath or similar measure calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests cancer associated variants for their colony forming ability, E3 ligase function and impact on ubiquitination of cyclin E.",
          "judgment": "Less than 10 pathogenic or benign controls.",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic or Benign/Likely Benign variants independently of this study. Since we don't have more than 10 known variants, the evidence is maxed at supporting.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E344G mutation compromises PARK2's ability to suppress tumor cell growth and impairs its E3 ligase function and this is PS3 supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "46"
        },
        "variant_string_id": "PARK2 A46T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper investigates the role of PARK2, an E3 ubiquitin ligase, as a tumor suppressor, contrasting its known role in Parkinson's disease where mutations lead to neuronal dysfunction. The disease mechanism in cancer involves the loss of PARK2's ubiquitin ligase activity, leading to dysregulation of cyclin E and promoting tumor cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism in cancer as the loss of PARK2's tumor suppressor function due to impaired ubiquitination activity, leading to increased cell growth and mitotic instability. This contrasts with the neuronal dysfunction seen in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses colony-forming assays, cell growth assays, xenograft studies, and ubiquitination assays to assess the impact of PARK2 mutations on tumor cell growth and cyclin E regulation.",
          "judgment": "Yes",
          "reasoning": "The assays used (colony-forming, cell growth, xenograft, and ubiquitination assays) are relevant to assessing the role of PARK2 as a tumor suppressor and its impact on cell proliferation and ubiquitination activity. These assays directly model the proposed disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type PARK2 as a normal/negative control and vector-only control. The paper explicitly states that multiple replicates were used for experiments.",
          "judgment": "Yes",
          "reasoning": "The study used a wild-type PARK2 control and a vector-only control. The assays were performed in triplicate, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study also included cancer-specific variants as controls. The study tests PARK2 with tumor-derived mutations resulted in substantially decreased colony-forming activity as compared to WT PARK2",
          "judgment": "No",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic variants independently of this study. Hence, we cannot proceed further with the PS3 evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using Student's t-test and ANOVA.",
          "judgment": "No",
          "reasoning": "The statistical analyses are insufficient to calculate OddsPath for the functional data for this variant. There is no OddsPath or similar measure calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests cancer associated variants for their colony forming ability, E3 ligase function and impact on ubiquitination of cyclin E.",
          "judgment": "Less than 10 pathogenic or benign controls.",
          "reasoning": "The cancer variants used in this study are not 'known' Pathogenic/Likely Pathogenic or Benign/Likely Benign variants independently of this study. Since we don't have more than 10 known variants, the evidence is maxed at supporting.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A46T mutation compromises PARK2's ability to suppress tumor cell growth and impairs its E3 ligase function and this is PS3 supporting evidence."
    }
  ]
}
```